EDINBURGH MOLECULAR IMAGING
See. Treat. Cure.
Highly Specific Cancer Targeting
Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.
Pipeline
EM Imaging has a portfolio of agents addressing a number of unmet medical needs
Ongoing Clinical Studies
EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section.
Our Latest News
Exceptional growth for Venture Capital Deals in radiopharmaceutical companies in 2023
GlobalData Reports that Venture Capital Deals in radiopharmaceutical companies have grown 550% to $408m in 2023 GlobalData reports that venture capital deals in radiopharmaceuticals have grown by...
Dr Lena Unterrainer presents data on [Ga-68]EMP-100 at EANM 2023
Dr Lena Unterrainer presented [Ga-68]EMP-100 as one of the "dark horses of theranostics" and showed the data of [Ga-68]EMP-100 in NSCLC.